Premium
Propylthiouracil and carbimazole associated‐antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves’ disease
Author(s) -
Harper L.,
Chin L.,
Daykin J.,
Allahabadia A.,
Heward J.,
Gough S. C.,
Savage C. O.,
Franklyn J. A.
Publication year - 2004
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2004.02029.x
Subject(s) - medicine , carbimazole , graves' disease , anti neutrophil cytoplasmic antibody , euthyroid , antithyroid agent , propylthiouracil , thyroiditis , endocrinology , immunology , gastroenterology , vasculitis , thyroid , disease
Summary objective Propylthiouracil treatment of Graves’ disease has been postulated to provoke antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis. We aimed to investigate whether carbimazole therapy was also associated with increased risk of ANCA. design The occurrence of ANCA and the relationship to thionamide treatment was investigated in a cross‐sectional study in a consecutive series of 407 patients’ with Graves’ disease, 200 with Hashimoto's thyroiditis and 649 normal euthyroid subjects. measurements ANCA was measured by indirect immunofluorescence (IIF) and enzyme‐linked immunosorbent assay (ELISA) for proteinase 3 and myeloperoxidase‐ANCA. results The prevalence of ANCA, as measured by IIF, was increased in the Graves’ disease cohort (19·9%) compared with euthyroid controls (4·6%; P < 0·001). The prevalence of MPO‐ANCA (measured by ELISA) was also increased in Graves’ disease ( P = 0·019). ANCA prevalence was more strongly associated with propylthiouracil treatment than carbimazole ( P = 0·0265), although risk of ANCA was also higher in Graves’ patients treated with carbimazole than controls (RR 2·2, P < 0·0001). ANCA positivity was not increased in patients with Hashimoto's thyroiditis. conclusion This study revealed a high prevalence of ANCA in treated patients with Graves’ disease but not in those with Hashimoto's thyroiditis. Furthermore, within the Graves’ disease population, ANCA development was associated with propylthiouracil usage to a greater extent than carbimazole. These findings suggest that the altered immune environment associated with autoimmune thyroid disease is not sufficient to develop ANCA but treatment with thionamides is important in promoting ANCA development.